Deepa Shivnani¹*, EV Raman¹, Shruthi Kobal¹, Sathwika¹ and Poonam Patil²

¹Children’s Airway and Swallowing Center, Department of Otolaryngology and Head and Neck Surgery, Manipal Hospitals, Bangalore, India
²Department of Radiation Oncology, Manipal Hospitals, Bangalore, India

*Corresponding Author: Deepa Shivnani, Children’s Airway and Swallowing Center, Department of Otolaryngology and Head and Neck Surgery, Manipal Hospitals, Bangalore, India.

Received: July 13, 2023; Published: September 06, 2023

Abstract

Recurrent Respiratory Papillomatosis (RRP) is a benign condition which needs frequent surgical interventions for debulking of papillomatosis lesions for securing the airway. There is no definitive treatment for the management of RRP so far. Bevacizumab either intralesional or systemic has emerged as a promising solution for RRP patients undergoing repeated surgeries. We are reporting a case of a 6-year-old child with juvenile onset RRP who was treated by surgical excision of lesion with adjuvant systemic bevacizumab therapy.

 Keyword: Recurrent Respiratory Papillomatosis; JORRP; Medical Treatment; Bevacizumab

References

1. Carifi M., et al. “Recurrent respiratory papillomatosis: current and future perspectives”. Therapeutics and Clinical Risk Management 11 (2015): 731-738.
2. Schraff S., et al. “American Society of Pediatric Otolaryngology members’ experience with recurrent respiratory papillomatosis and the use of adjuvant therapy”. Archives of Otolaryngology--Head and Neck Surgery 9 (2004): 1039-1042.
3. Best SR., et al. “Systemic bevacizumab for recurrent respiratory papillomatosis: a national survey”. Laryngoscope 10 (2017): 2225-2229.
4. Bedoya A., et al. “Systemic bevacizumab for recurrent respiratory papillomatosis: a single centre experience of two cases”. American Journal of Case Reports 18 (2017): 842-846.
5. Rahbar R., et al. “Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis”. Annals of Otology, Rhinology, and Laryngology 4 (2005): 289-295.
6. Mohr M., et al. “Rapid response to systemic Bevacizumab therapy in recurrent respiratory papillomatosis”. Oncology Letter 8 (2014): 1912-1918.
7. Taugourdeau-Raymond S., et al. “Bevacizumab induced serious side-effects: a review of the French pharmacovigi- lance database”. European Journal of Clinical Pharmacology 68 (2012): 1103-1107.
8. De Pasquale MD., et al. “Bevacizumab in pediatric patients: how safe is it?” Anticancer Research 31 (2011): 3953-3957.

Citation

Citation: Deepa Shivnani., et al. “Use of Adjuvant Intravenous Bevacizumab for Aggressive Recurrent Respiratory Papillomatosis - A Case Report".Acta Scientific Otolaryngology 5.10 (2023): 07-09.

Copyright

Copyright: © 2023 Deepa Shivnani., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.